306 related articles for article (PubMed ID: 30199098)
1. HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise.
Hendrix CW
Clin Pharmacol Ther; 2018 Dec; 104(6):1082-1097. PubMed ID: 30199098
[TBL] [Abstract][Full Text] [Related]
2. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
3. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.
Dolling DI; Desai M; McOwan A; Gilson R; Clarke A; Fisher M; Schembri G; Sullivan AK; Mackie N; Reeves I; Portman M; Saunders J; Fox J; Bayley J; Brady M; Bowman C; Lacey CJ; Taylor S; White D; Antonucci S; Gafos M; McCormack S; Gill ON; Dunn DT; Nardone A;
Trials; 2016 Mar; 17():163. PubMed ID: 27013513
[TBL] [Abstract][Full Text] [Related]
4. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
[TBL] [Abstract][Full Text] [Related]
5. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
7. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
Trang TP; Dong BJ; Kojima N; Klausner JD
Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
[TBL] [Abstract][Full Text] [Related]
8. Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.
Naicker CL; Mansoor LE; Dawood H; Naidoo K; Singo D; Matten D; Williamson C; Abdool Karim Q
BMC Infect Dis; 2020 Jul; 20(1):532. PubMed ID: 32698772
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.
Brooks KM; Anderson PL
Clin Pharmacol Ther; 2018 Dec; 104(6):1056-1059. PubMed ID: 30178462
[No Abstract] [Full Text] [Related]
10. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
11. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report.
Malahleha M; Ahmed K; Deese J; Nanda K; van Damme L; De Baetselier I; Burnett RJ
J Med Case Rep; 2015 Sep; 9():207. PubMed ID: 26411737
[TBL] [Abstract][Full Text] [Related]
13. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
[TBL] [Abstract][Full Text] [Related]
14. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
15. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
16. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
[TBL] [Abstract][Full Text] [Related]
17. Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection.
Stalter RM; Pintye J; Mugwanya KK
Expert Opin Drug Saf; 2021 Nov; 20(11):1367-1373. PubMed ID: 33998936
[No Abstract] [Full Text] [Related]
18. MOVING FORWARD WITH PrEP. THE BASICS OF PrEP.
Highleyman L
Posit Aware; 2015; 27(5):2-3. PubMed ID: 26714333
[No Abstract] [Full Text] [Related]
19. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
Noret M; Balavoine S; Pintado C; Siguier M; Brun A; Bauer R; Loze B; Leplatois A; Aslan A; Moudachirou K; Delaugerre C; Rozenbaum W; Molina JM
AIDS; 2018 Sep; 32(15):2161-2169. PubMed ID: 30212403
[TBL] [Abstract][Full Text] [Related]
20. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
Özdener AE; Park TE; Kalabalik J; Gupta R
Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
